0001317757-11-000029.txt : 20111220 0001317757-11-000029.hdr.sgml : 20111220 20111220160452 ACCESSION NUMBER: 0001317757-11-000029 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20111219 FILED AS OF DATE: 20111220 DATE AS OF CHANGE: 20111220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: White Christopher G CENTRAL INDEX KEY: 0001537668 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 111272130 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 3 1 primary_doc.xml PRIMARY DOCUMENT X0204 3 2011-12-19 0 0000792977 AMAG PHARMACEUTICALS INC. AMAG 0001537668 White Christopher G C/O AMAG PHARMACEUTICALS, INC. 100 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Business Officer and SVP Stock Options 54.66 2017-09-04 Common Stock 15000 D Stock Options 47.08 2018-02-26 Common Stock 14000 D Restricted Stock Units Common Stock 3750 D Stock Options 34.26 2019-02-25 Common Stock 20000 D Restricted Stock Units Common Stock 2500 D Stock Options 38.29 2020-02-24 Common Stock 10000 D Restricted Stock Units Common Stock 16000 D Restricted Stock Units Common Stock 4000 D Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2000 Stock Plan. This grant vested in four equal installments on September 4, 2008, September 4, 2009, September 4, 2010 and September 4, 2011. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one, two and three vested on February 26, 2009, February 26, 2010 and February 26, 2011, respectively. The fourth installment will vest on February 26, 2012. Grant of 15,000 restricted stock units pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on August 5, 2010, 25% on August 5, 2011 and the remaining 25% on August 5, 2012. Not applicable. Each restricted stock unit represents a contingent right to receive one share of common stock. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one and two vested on February 25, 2010 and February 25, 2011, respectively. The remaining two installments will vest on February 25, 2012 and February 25, 2013. Grant of 3,333 restricted stock units pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on February 24, 2011. Installments two, three and four will vest on February 24, 2012, February 24, 2013 and February 24, 2014, respectively. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on February 24, 2011. Installments two, three and four will vest on February 24, 2012, February 24, 2013 and February 24, 2014, respectively. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on January 7, 2012, 25% on January 7, 2013 and the remaining 25% on January 7, 2014. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in its entirety in a single installment on the earlier to occur of: January 7, 2015, or immediately prior to a change of control of the Company, provided that in either case the closing price of the Company's stock is at least $30.00 per share. Joseph L. Farmer, attorney-in-fact 2011-12-20 EX-99 2 powerofattorney.txt POWER OF ATTORNEY POWER OF ATTORNEY For Executing Forms 3, 4 and 5 Know all by these present,that the undersigned hereby constitutes and appoints each of Frank Thomas and Joseph Farmer, signing singly, his true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned,in the undersigneds capacity as an officer and/or director of AMAG Pharmaceuticals, Inc., or the Company, Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Forms 3, 4 and 5 and the timely filing of such forms with the United States Securities and Exchange Commission and any other authority; and (3) take any other action of any type whatsoever in connection with the foregoing which,in the opinion of such attorney-in-fact may be of benefit to,in the best interest of,or legally required by,the undersigned,it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted,as fully to all intents and purposes as the undersigned might or could do if personally present,with full power of substitution or revocation hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigneds responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney replaces in their entirety any and all prior powers of attorney executed by the undersigned with respect to the subject matters set forth herein, including any powers of attorney previously filed with the Securities and Exchange Commission. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigneds holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 19th day of December 2011. Signed: /s/ Christopher G. White Please Print: Christopher G. White